Creon Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established efficacy of pancrelipase, rising cystic fibrosis population, increased pancreatic surgery rates, improved diagnosis of exocrine pancreatic insufficiency, gastroenterology driven prescriptions.

The growth in the forecast period can be attributed to growth in chronic digestive disorders, rising aging population, improved nutritional management focus, expansion of outpatient digestive care, increased awareness of enzyme deficiencies. Major trends in the forecast period include strong adoption of pancrelipase based therapies, growing focus on pancreatic enzyme replacement therapy, expansion of long term digestive disorder management, improved patient compliance through optimized dosing, rising use in post pancreatic surgery care.

The rising prevalence of pancreatic disorders is expected to drive the growth of the Creon market in the coming years. Pancreatic disorders are a group of conditions that affect the pancreas, impairing its ability to produce digestive enzymes and/or insulin, which can lead to problems with digestion, blood sugar regulation, and overall health. The incidence of pancreatic disorders is increasing due to factors such as chronic alcohol consumption, smoking, obesity, diabetes, genetic predispositions, and improved diagnostic techniques that enable greater detection. Creon is used to manage pancreatic disorders by supplementing digestive enzymes to support digestion and nutrient absorption. For example, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that new pancreatic cancer cases in the UK are projected to rise from approximately 12,500 annually between 2023 and 2025 to around 16,000 by 2038-2040, representing a 5% increase in incidence and averaging 19 cases per 100,000 people by that time. Therefore, the rising prevalence of pancreatic disorders is fueling the growth of the Creon market.

The increasing healthcare expenditure is expected to support the expansion of the Creon market. Healthcare expenditure refers to total spending on medical services, treatments, pharmaceuticals, and healthcare infrastructure. This growth is driven by factors such as aging populations, rising demand for medical services, higher treatment costs, and advancements in healthcare technology. Higher healthcare expenditure enhances accessibility and affordability of Creon for patients with pancreatic disorders, influencing its widespread adoption. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. Consequently, rising healthcare expenditure is supporting the growth of the Creon market.

The growing focus on personalized medicine is expected to further propel the growth of the Creon market. Personalized medicine is a medical approach that tailors treatment based on an individual patient’s genetic profile, environment, and lifestyle to optimize effectiveness and minimize side effects. This focus is driven by advancements in genetics, improved understanding of diseases, the demand for more effective therapies, and the use of technologies such as AI to develop customized treatments. Personalized medicine benefits Creon by enabling more precise enzyme replacement therapy tailored to each patient’s specific pancreatic condition, improving treatment outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the Creon market.

Major companies operating in the creon market are AbbVie Inc.

North America was the largest region in the creon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the creon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the creon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the creon market by increasing costs related to enzyme production, encapsulation processes, and international distribution. These impacts are most visible across hospital pharmacies and retail pharmacy channels. Higher tariffs have added pricing pressure on long term digestive therapies. At the same time, tariffs are promoting localized manufacturing and supply chain diversification. This is improving long term availability of pancrelipase based treatments.

The creon market research report is one of a series of new reports that provides creon market statistics, including creon industry global market size, regional shares, competitors with a creon market share, detailed creon market segments, market trends and opportunities, and any further data you may need to thrive in the creon industry. This creon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Creon is a prescription medication containing pancrelipase, a blend of digestive enzymes including lipase, protease, and amylase. These enzymes, normally produced by the pancreas, assist in food digestion. Creon is used to treat conditions where the pancreas does not produce sufficient enzymes, such as cystic fibrosis, chronic pancreatitis, or following pancreatic surgery. By supplementing the body’s enzyme levels, Creon improves the digestion and absorption of fats, proteins, and carbohydrates, which are vital nutrients. It is taken orally with meals and snacks to aid digestion.

The main types of Creon treatment include nutritional management and pancreatic enzyme replacement therapy (PERT). Nutritional management involves planning and controlling a person’s diet to support health, recovery, and overall well-being. Creon is used for symptoms such as abdominal pain, constipation, diarrhea, fatty stools, and weight loss, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The creon market consists of sales of pancreatic enzyme supplements, digestive health supplements, pancreatic enzyme replacement therapy (PERT) devices, and nutritional supplements for digestive health. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.